About Impel

Impel Neuropharma, Inc. is a private Seattle based company developing intranasal drug treatments for central nervous system (CNS) disorders. We have developed a novel drug delivery platform, the POD™ technology, that administers medicine deep into the nasal cavity. The POD™ technology achieves consistent and predictable biodistribution of the medicine to improve clinical outcomes for patients.

Credit: BioMed Realty

Philosophy

________________________

We want to develop the next generation of therapeutics for central nervous system (CNS) disorders. We believe that intranasal delivery is a vastly underutilized route of drug administration that holds great promise in addressing unmet needs for patients managing CNS disorders. We strive daily to utilize our knowledge and technology to deliver better outcomes for patients.

How it started

Impel was founded in Seattle in 2008 and was spun out of the University of Washington in 2010. The founders, including Impel’s Chief Scientific Officer John Hoekman, Ph.D., began Impel by researching the pharmacokinetics of drugs delivered to the upper nasal cavity. They discovered that targeting the upper nasal cavity could result in more consistent and predictable drug delivery. Dr. Hoekman then began developing an intranasal device platform that could utilize this pathway and that led to the POD™ technology that is the driving force behind Impel.